Related Experiment Videos
Ceftriaxone and otitis in children: new indication. Only in special circumstances
Insights
Ceftriaxone offers an effective intramuscular treatment for acute otitis media in children. While generally well-tolerated, injection site pain is the primary side effect noted in clinical trials.
Area of Science:
- Pediatric infectious diseases
- Pharmacology of antibiotics
- Clinical trial analysis
Background:
- Ceftriaxone, a third-generation cephalosporin, is approved in France for treating acute otitis media (AOM) in children.
- It is indicated for both first-line therapy in children under 30 months and as a second-line treatment following initial antibiotic regimen failure.
Purpose of the Study:
- To evaluate the efficacy and safety of ceftriaxone for acute otitis media in pediatric patients.
- To compare ceftriaxone's effectiveness against other common antibiotic treatments for AOM.
Main Methods:
- Review of clinical trial data for first-line ceftriaxone treatment.
- Analysis of limited non-comparative trials for ceftriaxone used after initial treatment failure.
Main Results:
- First-line ceftriaxone demonstrated efficacy comparable to oral amoxicillin, sulfamethoxazole + trimethoprim, and amoxicillin + clavulanic acid.
- A single intramuscular dose of ceftriaxone showed similar effectiveness to 10-day oral antibiotic courses.
Conclusions:
- Intramuscular ceftriaxone is an effective therapeutic option for acute otitis media in children.
- The main adverse effect is injection site pain, even with the inclusion of lidocaine.
Abstract:
(1) Ceftriaxone, a third-generation cephalosporin antibiotic, is now licensed in France for (intramuscular) treatment of acute otitis media in children, both as first-line therapy in children under 30 months, and after failure of a first antibiotic regimen. (2) The clinical file on first-line ceftriaxone treatment is relatively bulky. In contrast, only two non comparative trials of ceftriaxone after failure of initial treatment are available. (3) According to trials of first-line treatment, the efficacy of a single intramuscular dose of ceftriaxone is equivalent to that of the sulfamethoxazole + trimethoprim combination and the amoxicillin + clavulanic acid combination, and similar to that of amoxicillin (when all these reference antibiotics are given orally for 10 days). (4) Pain at the injection site is the main adverse effect of ceftriaxone, despite the local anaesthetic (lidocaine) contained in the solvent.